Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with insulin glargine U100

Munich, Germany, 13 September 2016 - Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy® (IDegLira) compared to up-titration with insulin glargine U100 in adults with type 2 diabetes uncontrolled on insulin glargine U100 (20-50 units). Xultophy® is the first once-daily combination of a long-acting insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1) receptor agonist (liraglutide) in Europe. Results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.1

Read the full release including references

Further information

Media:
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Åsa Josefsson +45 3079 7708 aajf@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

_______________________

References

1.         Lingvay I, Norwood P, Begtrup K et al. Patients with T2D Treated with IDegLira Have a Greater Chance of Reaching Glycaemic targets without Hypoglycaemia and Weight Gain than with Insulin Glargine U100 (IGlar U100).
Abstract 890 presented at the 52nd European Association for the Study of Diabetes (EASD), Munich, Germany. 13 September 2016.